HC Wainwright: Why The Upside Potential For Palatin Technologies Is Nearly Fivefold


20-Year Pro Trader Reveals His "MoneyLine"

Ditch your indicators and use the "MoneyLine". A simple line tells you when to buy and sell without the guesswork. It’s a line on a chart that’s helped Nic Chahine win 83% of his options buys. Here's how he does it.


Palatin Technologies, Inc. (NYSE:PTN), a biopharmaceutical company that focuses on treatments for diseases with significant unmet medical needs, boasts a lead asset, bremelanotide, that has an "arousing number of major boxes checked," according to H.C. Wainwright.

The Analyst

H.C. Wainwright & Co's Joseph Pantginis initiated coverage of Palatin Technologies' stock with a Buy rating and $5 price target.

The Thesis

Bremelanotide, a treatment for hypoactive sexual desire disorder in women, offers investors a "derisked opportunity" for three reasons, Pantginis said in the initiation note. They are:

  • A New Drug Application was already filed with the FDA on March 26.
  • Two Phase 3 studies yielded positive results.
  • A North American partnership is already in place with AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG).
  • Regional partnerships in China and Korea are already established.

Four more potential catalysts are not presently reflected in Palatin's share price, Pantginis said: 

  • Expectations for a partnership in Europe.
  • The potential to become the first company to have a first-in-class and best-in-class drug for an unaddressed market.
  • Expectations for full FDA approval.
  • A management team with proven execution.

Price Action

Shares of Palatin Technologies were trading higher by 3.33 percent at the time of publication Friday. 

Benzinga Pro's 5 Stocks To Watch Today

Benzinga's Top Upgrades, Downgrades For April 6, 2018


20-Year Pro Trader Reveals His "MoneyLine"

Ditch your indicators and use the "MoneyLine". A simple line tells you when to buy and sell without the guesswork. It’s a line on a chart that’s helped Nic Chahine win 83% of his options buys. Here's how he does it.


ENTER TO WIN $500 IN STOCK OR CRYPTO

Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!

Posted In: Analyst ColorHealth CarePrice TargetInitiationAnalyst RatingsGeneralBiopharmaceuticalbremelanotideHC WainwrightHypoactive Sexual DesireJoseph Pantginis